Targeting PDE7 by the small molecule S14: A potential disease-modifying Parkinson�s disease therapy ready to start clinical trials
Objective: The main goal of this work is the regulatory chemical, pharmaceutical and toxicological development of S14, a new therapeutic class for the potential treatment…A comparison of deep brain stimulation and continuous intrajejunal levodopa infusion in advanced Parkinson’s disease: The INVEST study
Objective: To compare costs and effectiveness of the therapies DBS and CLI in advanced PD. Background: The therapies deep brain stimulation (DBS) and continuous intrajejunale…Does distance walked after two minutes predict total 6 minute walk test distance in people with Parkinson’s disease?
Objective: To determine if the distance walked in the first two minutes of the 6 Minute Walk Test (6MWT) accurately predicts the total distance walked…Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation
Objective: To evaluate the pharmacological properties of Adenosine A2A receptor antagonist, istradefylline (IST), and analyze A2AR protein levels of peripheral lymphocytes and the frequency of…Pisa syndrome in Parkinson’s disease: A mobile orfixed deformity?
Objective: To study of Pisa syndrome in Parkinson's disease. Background: Although Pisa syndrome and scoliosis are sometimes used interchangeably to describe a laterally flexed postural…Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms
Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy
Objective: Here we report the case of a 49-year-old man with a 19 years history of PD presenting DDS while he was on LCIG therapy.…Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease
Objective: The aim of this study was to characterize the levodopa and carbidopa plasma concentration in relation to blinded motor function ratings. This is a…Feasibility, safety and effects of a group intervention based on European physiotherapy guideline for Parkinson´s disease
Objective: To assess the feasibility, safety and effects of an group intervention based on European Physiotherapy Guideline. Background: Studies suggest that exercise may contribute to…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 207
- Next Page »